DOI: https://doi.org/10.21203/rs.3.rs-117193/v1
Background
One of the common sustained cardiac arrhythmia disorders is atrial fibrillation (AF), nowadays, results concerning the associations between ZFHX3/PRRX1 genes and AF has been widely reported. A meta-analysis to confirm above associations is necessary to be carried out in time.
Methods
The PubMed, Embase and Wanfang databases were conducted for searching, covering all publications before 20th July, 2020.
Results
Overall, seven articles including 3,674 cases and 8,990 healthy controls about ZFHX3 rs2106261 and 1045 cases and 1407 controls for PRRX1 rs3903239 were included. Odds ratio (OR)[95% confidence interval (CI)] was applied to assess the associations. Publication bias was calculated by both Egger’s and Begg’s tests. After calculated, we found that ZFHX3 rs2106261 polymorphism potential increased AF risk in Asians (for example: allelic contrast: OR [95%CI]: 1.39[1.31-1.47], P < 0.001). Similarly, stratified analysis by source of control and genotype method, also increased associations were detected (for example: allelic contrast: OR[95%CI] = 1.51[1.38-1.64], P < 0.001 for HB; OR[95%CI]: 1.31[1.21-1.41], P < 0.001 for PB; OR[95%CI] = 1.55[1.33-1.80], P < 0.001 for TaqMan; OR[95%CI] = 1.31[1.21-1.41], P < 0.001 for HRM). On the other hand, decreased relationship was observed between PRRX1 rs3903239 polymorphism and AF risk (C-allele vs. T-allele: OR[95%CI] = 0.83[0.77-0.99], P = 0.036; CT vs. TT: OR[95%CI] = 0.79[0.67-0.94], P = 0.006). No obvious evidence of publication bias was found.
Conclusions
In summary, our study suggested that ZFHX3 rs2106261 and PRRX1 rs3903239 polymorphisms had positive associations with AF risk, more large case-controls must be carried out to confirm above conclusions.
Atrial fibrillation (AF) is one of the common forms of arrhythmia in clinics, about 1-2% incidence among adults worldwide[1, 2]. Previous studies have demonstrated that AF significantly increases the social and economic burden both in developed and developing countries[3]. AF is also a main cause of heart failure and stroke[4, 5]. A variety of structural heart diseases and systemic diseases are related to AF, including congestive heart failure, cardiomyopathy, pulmonary heart disease, essential hypertension, and hyperthyroidism[6, 7], while age, obesity, smoking, excessive drinking and drug use have also been contributed to the development of AF[6, 8]. So far, the exact pathogenesis of AF is still unclear. However, many evidences support that genetic factors play an important role in its occurrence and development[9]. In fact, common genetic variants (a multitude of single-nucleotide polymorphism, SNPs) associated with AF have been detected in Genome-wide association studies (GWAS)[10-12]: such as endothelial nitric oxide synthase 786T/C, CYP11B2 rs1799998, KCNE1 G38S, Caveolin-1 rs3807989[9, 13-15].
Two independent GWAS identified significant associations between rs2106261 and rs7193343 polymorphisms in zinc finger homeobox 3 (ZFHX3) gene and AF susceptibility in various populations of European ancestry[16, 17], which locates on chromosome 16q22 and encodes zinc finger homeobox 3. The specific contents were as follows: Benjamin et al.[16] indicated that rs2106261 SNP in ZFHX3 gene was associated with AF (OR = 1.19; P = 2.76×10-7), in the same period, Gudbjartsson et al.[17] assessed another SNP (rs7193343) in ZFHX3, which was confirmed to be related to AF in the Icelandic individuals (OR = 1.21, P = 1.4×10-10).
The paired related homeobox 1 (PRRX1) encodes a homeodomain transcription factor that is highly expressed in the developing heart[18]. In the PRRX1 knockout mouse model, fetal lung vascular development is impaired[19]. In addition, the expression pattern of PRRX1 in the mouse atria was evaluated. Compared with the right atrium, both proteins were overexpressed in the left atrium[20]. Above results suggested PRRX1 may play a vital role in heart disease, including AF. In a subsequent meta-GWAS, PRRX1 rs3903239 variant was associated with AF risk (P = 8.4 × 10-14) [21].
Taking into consideration of a more precise assessment of ZFHX3 rs2106261 and PRRX1 rs3903239 variants in AF risk, hence, we must first perform a meta-analysis of all eligible case-control studies to confirm[18, 22-27].
Identification and eligibility of relevant studies
The PubMed, Embase and Wanfang databases were selected, last search was updated on July 20, 2020, with the keywords containing ‘ZFHX3’ or ‘zinc finger homeobox 3’, ‘PRRX1’ or ‘paired related homeobox 1’, ‘polymorphism’ or ‘variant’ and ‘atrial fibrillation’. After above search, a total of 96 publications were identified, of which 7 articles coincide following inclusion criteria.
The criteria for inclusion and exclusion
The research included in the analysis must meet all of the following conditions: (a) the study assessed the correlation between AF and ZFHX3 rs2106261 polymorphism and/or PRRX1 rs3903239 polymorphism; (b) unpaired case-control studies; (c) sufficient genotypes in cases and controls. The model number was for each group. Therefore, the following exclusion criteria were also applied: (a) no control group; (b) no genotype frequency was available and (c) previous publications was repeated.
Data extraction
Two of the authors extracted all data independently, complied with the selection criteria. The following items were collected: author’s name, ethnicity, year of publication, total or each genotype case/control number, original, source of control, genotyping methods and Hardy-Weinberg equilibrium (HWE) of controls.
Quality score assessment (NOS)
NOS was used to assess the quality of each study and evaluate all aspects of the methodology, including case selection, comparability between groups, and exposure determination. NOS has a total score of 0 to 9 stars. Research with a score greater than 7 is considered as high-quality study[28].
Statistic analysis
Based on the genotype frequencies of the cases and controls, the probability odds ratio (OR) with 95% confidence interval (CI) was used to measure the strength of association between the polymorphism of ZFHX3 rs2106261 polymorphism and PRRX1 rs3903239 polymorphism and AF. First to conduct a subgroup analysis stratified by race. The source of the control subgroup analysis was carried out in two categories: population-based (PB) and hospital-based (HB).
The statistical significance of OR was determined by Z-test. Using fixed effects model and random effects model to calculate the combined OR. The Q-test (P ≥ 0.10) indicates that there is heterogeneity between including studies. If significant heterogeneity is detected, the random effects model (DerSimonian-Laird method) is used, but the fixed effects model (Mantel-Haenszel method) is selected [29, 30]. For ZFHX3 rs2106261, we investigated the relationship between genetic variants and AF risk in allelic contrast (A-allele versus G-allele), homozygote comparison (AA versus GG), dominant genetic model (AA+AG versus GG), heterozygote comparison (AG versus GG), and recessive genetic model (AA versus AG+GG). For PRRX1 rs3903239, C-allele vs, T-allele, CT vs. TT, CC vs. TT, CC+CT vs. TT and CC vs. CT+TT models was applied. Funnel plot asymmetry was assessed using Begg’s test and publication bias was assessed using Egger’s test [31]. The departure of frequencies of from expectation under HWE was assessed by χ2 test in controls using the Pearson chi-square test (P < 0.05 was considered significant) [32]. All statistical tests for this meta-analysis were performed with Stata software (version 11.0; StataCorp LP, College Station, TX).
Gene interaction network of ZFHX3 and PRRX1 gene
In order to fully understand the role and potential and functional partners of ZFHX3 and PRRX1 in AF, respectively, String online server (http://string-db.org/) uses the gene-gene interaction network of ZFHX3 and PRRX1 genes [33] (Figure 10).
Eligible studies
In total, nighty-six articles were collected from the PubMed, Embase and Wanfang databases. 89 articles were excluded (25-irrelated articles, 4-systematic/Meta-analysis, 1-only case group, 23-supplement, 30-duplication and 6-no original numbers for case/control groups) (Figure 1). Finally, seven articles were identified in current analysis, including 3,674 cases and 8,990 healthy controls related to ZFHX3 rs2106261 polymorphism and 1045 cases and 1407 controls for PRRX1 rs3903239 polymorphism. The characteristics of each included study are listed in Table 1. In addition, the Minor Allele Frequency (MAF) reported from the five main worldwide populations in the 1000 Genomes Browser are checked (https://www.ncbi.nlm.nih.gov/snp/): African; European; East Asian; American and South Asian (Figure 2), which was similar with the average level in our current case and control groups.
Meta-analysis
ZFHX3 rs2106261 polymorphism and AF risk
In the overall analysis, significantly increased associations was observed in five genetic models in Asians: in the allelic contrast (OR[95% CI] = 1.39[1.31-1.47], Pheterogeneity = 0.117, P < 0.001, Figure 3A), the heterozygote comparison (OR[95% CI] =1.37[1.18-1.59], Pheterogeneity = 0.007, P < 0.001, Figure 3B), AA vs. CC (OR[95% CI] = 1.96[1.73-2.21], Pheterogeneity = 0.317, P < 0.001, Figure 3C), the dominant model (OR [95% CI] = 1.49[1.30-1.70], Pheterogeneity = 0.011, P < 0.001, Figure 3D) and AA vs. AC +CC (OR[95% CI] = 1.70[1.52-1.90], Pheterogeneity = 0.643, P < 0.001, Figure 3E) (Table 2).
In the subgroup analysis by source of control, ZFHX3 rs2106261 A-allele or AA genotype acted as an risk factor in both HB and PB subgroups: HB (such as: A-allele versus C-allele: OR[95% CI] = 1.51[1.38-1.64], P(heterogeneity) = 0.302, P < 0.001; AC versus CC: OR[95% CI] = 1.57[1.38-1.79], P(heterogeneity) = 0.156, P < 0.001) and PB (such as: A-allele versus C-allele: OR[95% CI] = 1.31[1.21-1.41], P(heterogeneity) = 0.321, P < 0.001; AC versus CC: OR[95% CI] = 1.17[1.04-1.30], P(heterogeneity) = 0.584, P = 0.007) (Figure 3A,B, Table 2).
To detect whether the association were existed between genotype methods and ZFHX3 rs2106261 polymorphism, we carried out the next step. Several positive results were found in TaqMan [in the allelic contrast (OR = 1.55, 95% CI = 1.33-1.80, P = 0.740 for heterogeneity, P < 0.001 for significant), the heterozygote comparison (OR =1.82, 95% CI = 1.46-2.27, P = 0.668 for heterogeneity, P < 0.001), AA vs. CC (OR = 2.06, 95% CI = 1.48-2.86, Pheterogeneity = 0.884, P < 0.001 for significant), the dominant model (OR[95% CI] = 1.87[1.52-2.30], Pheterogeneity = 0.674, P < 0.001) and AA vs. AC +CC (OR[95% CI] = 1.51[1.11-2.06], Pheterogeneity = 1.000, P < 0.001), High-Resolution Melt (HRM) [in the allelic contrast (OR = 1.31, 95% CI = 1.21-1.41, Pheterogeneity = 0.647, P < 0.001), the heterozygote comparison (OR =1.17, 95% CI = 1.04-1.30, P = 0.584 for heterogeneity, P = 0.007 for significant), AA vs. CC (OR = 1.81, 95% CI = 1.54-2.12, Pheterogeneity = 0.417, P < 0.001), the dominant model (OR = 1.29, 95% CI = 1.16-1.43, P = 0.655 for heterogeneity, P < 0.001) and AA vs. AC +CC (OR = 1.68, 95% CI = 1.45-1.94, Pheterogeneity = 0.384, P < 0.001 for significant) and Others (data not shown) (Figure 4, Table 2).
PRRX1 rs3903239 polymorphism and AF risk
Decreased associations were found in heterozygote comparison (OR[95% CI] = 0.83[0.77-0.99], Pheterogeneity = 0.522, P = 0.036, Figure 5A, Table 2) and dominant model (OR[95% CI] = 0.79[0.67-0.94], P = 0.137 for heterogeneity,, P = 0.006, Figure 5B, Table 2).
Sensitivity analysis and publication bias
A Begg funnel chart and Egger test were performed to assess publication bias. The results did not show any evidence of publication bias (for example: A-allele versus G-allele, t = 1.46, P = 0.205 [Egger test]; z = 1.2, P = 0.23[Begg test] for ZFHX3 rs2106261, Figure 6; C-allele versus T-allele, t = 0.11, P = 0.933 [Egger test]; z = 0.0, P = 1.00 [Begg test] for PRRX1 rs3903239, Figure 7, Table 3). A sensitivity analysis was performed to assess the impact of each individual study on the combined OR by removing individual studies one by one. The results suggested that no separate study significantly affected the overall OR for ZFHX3 rs2106261 (Figure 8).
Network of gene-gene interaction of ZFHX3 and PRRX1 gene, respectively.
The network of potential gene-gene interaction for ZFHX3 and PRRX1 genes was analyzed by String online webpage (http://string-db.org/) [33] (Figure 9). Each gene was shown ten significant related genes in the web of relationships.
AF is considered to be the most common supraventricular arrhythmia, affecting up to 1% in the natural population[34, 35]. With the increase of age, the prevalence rate increases year by year, and the incidence of elderly cases (≥ 80years) can reach 8%[36]. Many types of heart and medical diseases that increase the risk of AF over age, which included arterial hypertension, cardiomyopathies, obstructive sleep apnea and valve dysfunction[37, 38]. In addition, based on a recent meta-analysis of GWAS for AF[11], more than 100 AF risk genetic mutations and polymorphisms have been reported, indicating that genetics may be participate in the mechanisms of AF. More and more studies have shown that genetic variation may promote to the pathophysiology of AF by altering the structure, proteins expression and function related to various cellular activities[39].
So far, several meta-analyses about gene polymorphisms and AF susceptibility have been published: such as chromosome 4q25 variants, CYP11B2 -344T>C, mink S38G, and so on[40-43]. A growing number of papers have pointed to polymorphisms from both ZFHX3 and PRRX1 genes. ZFHX3 rs2106261 and PRRX1 rs3903239 polymorphisms have been paid attention and have not reported through meta-analysis to clarify the associations to AF susceptibility.
Current analysis is the first evaluation to the associations among ZFHX3 rs2106261 and PRRX1 rs3903239 polymorphisms and AF risk involving 4719 cases and 10397 controls. The main results of our analysis are that we found increased relationships between ZFHX3 rs2106261 and AF risk, on the contrary, PRRX1 rs3903239 polymorphism acted as a protective factor in AF development. In other words, individuals carried A-allele of ZFHX3 rs2106261 polymorphism may have a high possible to be get AF; individuals taken along CC or CT genotype might have a decreased risk for AF, which can give us some warnings to reduce the incidence of AF: such as early detection, healthy life, pay more attention to the prevention. Different genes or variant polymorphisms in the same genes may play multifarious functions in the progress of AF, which should be explained above conclusions.
In addition, the online analysis system-String was applied to predict the potential and functional partners, which may help to expand the range of vision of related genes. Finally, ten genes were opened up. The first three highest score of association was CDKN1A (Score = 0.921), RUNX3 (Score = 0.918) and TGFβ1 (Score = 0.900). Several studies have been focused on CDKN1A and TGFβ1, not RUNX3, in the development of AF. Further studies should be pay attention to above three potential related genes and their common polymorphisms and AF risk. On the other hand, the score of related genes for PRRX1 is general low, which should be proofed and indicated in the future research.
Although positive results were found, limitations in current study should also be discussed. Beginning, the literature included is relatively new, the number of published studies remains not sufficiently larger. Second, the interactions between gene-gene/gene-environment (other covariates including family history, age, sex, disease stage and lifestyle), and even variants polymorphisms in the same genes may regulate AF risk, which must be included in further studies. Third, there are several types of AF: such as persistent, permanent, pathologic, idiopathic and paroxysmal. If enough data for one concrete AF, we should classify to one subgroup and analyze the association for ZFHX3 rs2106261 and PRRX1 rs3903239 polymorphisms, which is better to offer a guide to precision in the clinic.
Our analysis illustrated the proof that ZFHX3 rs2106261 and PRRX1 rs3903239 polymorphisms were related with conspicuous AF risk for Asians. Therefore, following well-designed and larger studies, including information about gene-gene/gene-environment interactions are recommended to confirm above conclusions.
AF, atrial fibrillation; ZFHX3, zinc finger homeobox 3; PRRX1, paired related homeobox 1, confidence intervals; HWE, Hardy–Weinberg equilibrium; OR, odds ratio.
Acknowledgements
Not applicable.
Author Contribution
L.W. conceived the study. M.C. searched the databases and extracted the data. W.Z. analyzed the data. L.W. wrote the draft of the paper. W.Z. reviewed the manuscript.
Funding
This article was supported by the Yangpu District Health and Family Planning Commission (YP18Q10) and Shanghai Yangpu District Key Discipline Project (YP19ZB03).
Availability of data and materials
All the data generated in the present research is contained in this manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Table 1 Characteristics of studies of ZFHX3 and PRRX1 genes’ two common polymorphisms and atrial fibrillation risk included in our meta-analysis
Author |
Year |
Country |
Ethnicity |
Case |
Control |
Case |
Control |
SOC |
HWE |
Genotype |
NOS |
|||||
ZFHX3 rs2106261 |
AA |
AG |
GG |
AA |
AG |
GG |
||||||||||
Okubo |
2020 |
Japan |
Asian |
289 |
287 |
46 |
143 |
99 |
32 |
109 |
146 |
HB |
0.096 |
TaqMan |
8 |
|
Zaw |
2017 |
Japan |
Asian |
411 |
1765 |
54 |
182 |
175 |
151 |
725 |
889 |
HB |
0.853 |
Illumina |
8 |
|
Huang |
2015 |
China |
Asian |
569 |
1996 |
99 |
237 |
233 |
216 |
869 |
911 |
PB |
0.683 |
HRM |
9 |
|
Huang |
2015 |
China |
Asian |
641 |
1692 |
103 |
279 |
259 |
197 |
707 |
788 |
PB |
0.048 |
HRM |
9 |
|
Huang |
2015 |
China |
Asian |
810 |
1627 |
128 |
369 |
313 |
149 |
726 |
752 |
PB |
0.163 |
HRM |
9 |
|
Liu |
2014 |
China |
Asian |
593 |
996 |
110 |
299 |
184 |
99 |
446 |
451 |
HB |
0.460 |
MassARRAY |
8 |
|
Tomomori |
2018 |
Japan |
Asian |
362 |
627 |
50 |
181 |
131 |
60 |
250 |
317 |
HB |
0.298 |
TaqMan |
8 |
|
PRRX1 rs3903239 |
CC |
CT |
TT |
CC |
CT |
TT |
||||||||||
Kalinderi |
2018 |
Greece |
European |
167 |
124 |
15 |
62 |
90 |
8 |
49 |
67 |
PB |
0.809 |
RCR-RFLP |
7 |
|
Okubo |
2020 |
Japan |
Asian |
287 |
287 |
29 |
139 |
119 |
59 |
143 |
85 |
HB |
0.935 |
TaqMan |
8 |
|
Liu |
2015 |
China |
Asian |
591 |
996 |
79 |
263 |
249 |
155 |
463 |
378 |
HB |
0.503 |
MassARRAY |
8 |
HB: hospital-based; PB: population-based; SOC; source of control; PCR-RFLP: polymerase chain reaction followed by restriction fragment length polymorphism; HRM: High-Resolution Melt; HWE: Hardy-Weinberg equilibrium of control group.
Table 2 Stratified analyses of ZFHX3 and PRRX1 genes’ two common polymorphisms on atrial fibrillation risk
Variables |
N |
Case/ |
M-allele vs. W-allele |
MW vs. WW |
MM+MW vs. WW |
MM vs. WW |
MM vs. MW+WW |
||||
ZFHX3 rs2106261 |
Control |
OR(95%CI) Ph P I2 |
OR(95%CI) Ph P I2 |
OR(95%CI) Ph P I2 |
OR(95%CI) Ph P I2 |
OR(95%CI) Ph P I2 |
|||||
Total |
7 |
3674/8990 |
1.39(1.31-1.47)0.117 0.000 41.1% |
1.37(1.18-1.59)0.007 0.000 66.5% |
1.49(1.30-1.70)0.011 0.000 63.6% |
1.96(1.73-2.21)0.317 0.000 14.8% |
1.70(1.52-1.90)0.643 0.000 0.0% |
||||
SOC |
|||||||||||
HB |
4 |
1654/3675 |
1.51(1.38-1.64)0.302 0.000 17.7% |
1.57(1.38-1.79)0.156 0.000 42.5% |
1.68(1.49-1.90)0.151 0.000 43.4% |
2.20(1.82-2.66)0.388 0.000 0.7% |
1.73(1.45-2.07)0.520 0.000 0.0% |
||||
PB |
3 |
2020/5315 |
1.31(1.21-1.41)0.321 0.000 0.0% |
1.17(1.04-1.30)0.584 0.007 0.0% |
1.29(1.16-1.43)0.655 0.000 0.0% |
1.81(1.54-2.12)0.417 0.000 0.0% |
1.68(1.45-1.94)0.384 0.000 0.0% |
||||
Genotype |
|||||||||||
TaqMan |
2 |
650/914 |
1.55(1.33-1.80) 0.740 0.000 0.0% |
1.82(1.46-2.27) 0.668 0.000 0.0% |
1.87(1.52-2.30) 0.674 0.000 0.0% |
2.06(1.48-2.86) 0.884 0.000 0.0% |
1.51(1.11-2.06) 1.000 0.000 0.0% |
||||
Other |
2 |
1004/2761 |
1.47(1.21-1.80)0.068 0.000 70.1% |
1.45(1.24-1.70)0.123 0.000 58.1% |
1.59(1.19-2.12)0.057 0.002 72.4% |
1.47(1.21-1.80)0.095 0.000 64.1% |
1.86(1.50-2.32)0.279 0.000 14.5% |
||||
HRM |
3 |
2020/5315 |
1.31(1.21-1.41)0.647 0.000 0.0% |
1.17(1.04-1.30)0.584 0.007 0.0% |
1.29(1.16-1.43)0.655 0.000 0.0% |
1.81(1.54-2.12)0.417 0.000 0.0% |
1.68(1.45-1.94)0.384 0.000 0.4% |
||||
PRRX1 rs3903239 |
|||||||||||
Total |
3 |
1045/1407 |
0.82(0.63-1.07)0.023 0.147 73.5% |
0.83(0.77-0.99)0.522 0.036 0.0% |
0.79(0.67-0.94)0.137 0.006 49.7% |
0.68(0.35-1.32)0.011 0.253 78.0% |
0.75(0.42-1.31)0.023 0.310 73.5% |
Ph: value of Q-test for heterogeneity test; P: Z-test for the statistical significance of the OR
Table 3 Publication bias tests (Begg’s funnel plot and Egger’s test for publication bias test)
Egger's test |
Begg's test |
|||||||
Genetic type |
Coefficient |
Standard error |
t |
P value |
95%CI of intercept |
z |
P value |
|
ZFHX3 rs2106261 |
||||||||
A-allele vs. G-allele |
3.372 |
2.313 |
1.46 |
0.205 |
(-2.573- 9.317) |
1.2 |
0.23 |
|
AG vs. GG |
2.523 |
1.507 |
1.67 |
0.155 |
(-1.351- 6.398) |
1.2 |
0.23 |
|
AA+AG vs. GG |
2.744 |
1.543 |
1.78 |
0.133 |
(-1.223- 6.712) |
1.2 |
0.23 |
|
AA vs. GG |
1.671 |
0.977 |
1.71 |
0.148 |
(-0.840- 4.182) |
1.2 |
0.23 |
|
AA vs. AG+GG |
1.690 |
1.083 |
1.56 |
0.179 |
(-1.094- 4.475) |
1.2 |
0.23 |
|
PRRX1 rs3903239 |
||||||||
C-allele vs. T-allele |
1.034 |
9.771 |
0.11 |
0.933 |
(-123.117-125.186) |
0.0 |
1.00 |
|
CT vs. TT |
0.496 |
7.243 |
0.07 |
0.956 |
(-91.538-92.531) |
0.0 |
1.00 |
|
CC+CT vs. TT |
0.471 |
7.530 |
0.06 |
0.960 |
(-95.213-96.154) |
0.0 |
1.00 |
|
CC vs. TT |
0.251 |
3.834 |
0.07 |
0.958 |
(-48.468-48.971) |
0.0 |
1.00 |
|
CC vs. CT+TT |
0.290 |
4.031 |
0.07 |
0.954 |
(-50.938-51.519) |
0.0 |
1.00 |
for ZFHX3 and PRRX1 genes’ two common polymorphisms (rs2106261 and rs3903239)